1. Home
  2. LBRDK vs COGT Comparison

LBRDK vs COGT Comparison

Compare LBRDK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation Class C

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$44.09

Market Cap

7.0B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.17

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDK
COGT
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LBRDK
COGT
Price
$44.09
$39.17
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
$30.17
AVG Volume (30 Days)
1.1M
2.4M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
1.38
N/A
EPS
5.51
N/A
Revenue
$1,016,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37.46
N/A
P/E Ratio
$8.02
N/A
Revenue Growth
306.40
N/A
52 Week Low
$43.77
$3.72
52 Week High
$104.00
$43.73

Technical Indicators

Market Signals
Indicator
LBRDK
COGT
Relative Strength Index (RSI) 31.41 60.74
Support Level $47.10 $33.84
Resistance Level $49.62 $36.88
Average True Range (ATR) 1.53 1.93
MACD -0.40 0.07
Stochastic Oscillator 4.63 75.53

Price Performance

Historical Comparison
LBRDK
COGT

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: